At the 2025 American Society of Clinical Oncology Genitourinary Cancers Symposium, Guru Sonpavde, MD, of AdventHealth Cancer Institute, showcases a phase I/Ib clincial trial on the safety of a neoadjuvant darolutamide and relugolix combination preceding radical prostatectomy for high risk localized and locally advanced prostate cancer.
Neoadjuvant Darolutamide, Relugolix Combination Before Radical Prostatectomy for High-Risk PC
By Guru P. Sonpavde, MD - Last Updated: February 24, 2025Related Posts
Dr. Keizman showcases his research on using Decipher for early prostate cancer for USA versus non-USA populations.
Dr. Ghoreifi characterizes the activity of inflammasome genes and their association with oncological outcomes in PC.
Patients with very high-risk disease saw greater benefit from long-term ADT use compared to those with high-risk disease.
Dr. Sanchez-Salas comments on whether PSMA PET is useful for determining optimal candidates for focal therapy.
Dr. Sanchez-Salas details strategies for selecting between focal therapy versus active surveillance or definitive treatments.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.